奥马珠单抗治疗慢性自发性荨麻疹患者：系统综述已发表的证据。
Omalizumab retreatment in patients with chronic spontaneous urticaria: a systematic review of published evidence.
机构信息
Institute of Clinical Physiology-National Research Council of Italy (IFC-CNR), Pisa, Italy.
Department of Emergency and Organ Transplantation, School and Chair of Allergology and Clinical Immunology, University of Bari Aldo Moro, Bari, Italy.
出版信息
Eur Ann Allergy Clin Immunol. 2020 May;52(3):100-103. doi: 10.23822/EurAnnACI.1764-1489.136. Epub 2020 May 5.
Abstract
A systematic review of the current literature on retreatment with omalizumab of patients with relapsing chronic spontaneous urticaria was performed. Published evidence shows that retreatment is safe and clinically effective, and that time to complete clinical response reduces as the number of retreatments increases.
摘要
对奥马珠单抗治疗复发性慢性自发性荨麻疹患者的现有文献进行了系统性回顾。已发表的证据表明，再次治疗是安全且临床有效的，且随着治疗次数的增加，达到临床缓解的时间缩短。
相似文献
1
Omalizumab retreatment in patients with chronic spontaneous urticaria: a systematic review of published evidence.奥马珠单抗治疗慢性自发性荨麻疹患者：系统综述已发表的证据。
Eur Ann Allergy Clin Immunol. 2020 May;52(3):100-103. doi: 10.23822/EurAnnACI.1764-1489.136. Epub 2020 May 5.
2
The use of omalizumab for treatment-refractory chronic spontaneous urticaria in a West Australian outpatient cohort.在西澳大利亚门诊队列中，奥马珠单抗治疗难治性慢性自发性荨麻疹的应用。
Intern Med J. 2019 Apr;49(4):526-528. doi: 10.1111/imj.14245.
3
Omalizumab is effective in patients with chronic spontaneous urticaria plus multiple chronic inducible urticaria.奥马珠单抗对慢性自发性荨麻疹合并多种慢性诱导性荨麻疹患者有效。
Eur Ann Allergy Clin Immunol. 2021 Mar;53(2):91-93. doi: 10.23822/EurAnnACI.1764-1489.153. Epub 2021 Mar 1.
4
Age and fast initial response predict omalizumab retreatment in chronic urticaria.年龄和快速初始反应可预测慢性荨麻疹患者的奥马珠单抗再治疗情况。
J Allergy Clin Immunol Pract. 2023 Nov;11(11):3556-3558.e1. doi: 10.1016/j.jaip.2023.07.030. Epub 2023 Jul 28.
5
Efficacy of omalizumab in chronic spontaneous urticaria associated with chronic inducible urticaria.奥马珠单抗治疗与慢性诱导性荨麻疹相关的慢性自发性荨麻疹的疗效
Ann Allergy Asthma Immunol. 2020 Oct;125(4):486-487. doi: 10.1016/j.anai.2020.06.011. Epub 2020 Jun 13.
6
Omalizumab re-treatment rates in chronic spontaneous urticaria.奥马珠单抗在慢性自发性荨麻疹中的再治疗率。
Eur Ann Allergy Clin Immunol. 2020 May;52(4):187-189. doi: 10.23822/EurAnnACI.1764-1489.145. Epub 2020 May 7.
7
H1-Antihistamines May No Longer Be Necessary for Patients With Refractory Chronic Spontaneous Urticaria After Initiation of Omalizumab.对于难治性慢性自发性荨麻疹患者，在开始使用奥马珠单抗后，H1抗组胺药可能不再必要。
J Investig Allergol Clin Immunol. 2020 Apr 24;30(2):145-147. doi: 10.18176/jiaci.0464. Epub 2019 Nov 25.
8
Total IgE and atopic status in patients with severe chronic spontaneous urticaria unresponsive to omalizumab treatment.对奥马珠单抗治疗无效的重度慢性自发性荨麻疹患者的总IgE及特应性状态
Allergy. 2019 Aug;74(8):1561-1563. doi: 10.1111/all.13754. Epub 2019 Mar 11.
9
Characteristics of patients with chronic spontaneous urticaria showing early and complete responses to omalizumab.对奥马珠单抗表现出早期和完全反应的慢性自发性荨麻疹患者的特征
Ann Allergy Asthma Immunol. 2021 Sep;127(3):394-395. doi: 10.1016/j.anai.2021.05.031. Epub 2021 Jun 6.
10
Use of omalizumab in uncontrolled chronic spontaneous urticaria also improved latex-induced contact urticaria.在控制不佳的慢性自发性荨麻疹中使用奥马珠单抗也改善了乳胶诱导的接触性荨麻疹。
J Allergy Clin Immunol Pract. 2019 Jan;7(1):300-302. doi: 10.1016/j.jaip.2018.05.005. Epub 2018 May 23.
引用本文的文献
1
Therapeutical Targets in Allergic Inflammation.过敏性炎症的治疗靶点
Biomedicines. 2022 Nov 9;10(11):2874. doi: 10.3390/biomedicines10112874.
Zotero 插件